NASDAQ | VICL: 1.00  -0.03


AnGes has applied Vical's technologies to the local delivery of a gene that encodes an angiogenic growth factor that promotes the growth of blood vessels. AnGes announced that it had reached agreement with the FDA regarding a Special Protocol Assessment for a Phase 3 clinical trial of its angiogenesis product, Collategene™ (HGF plasmid), and that the FDA has granted “Fast Track” designation to Collategene™ as a treatment for critical limb ischemia (CLI), the severest form of PAD. AnGes is poised to start a global Phase 3 clinical trial of  Collategene™ in patients with CLI. AnGes is also conducting a Phase 1/2 study for the treatment of primary lymphedema in Japan, for which the results are expected in the latter half of 2014.
P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.